Molecular Subtype
HER2-Positive Breast Carcinoma
CI-CAN-00007795Explore in graph →
140 active trials3 approved drugs93 evidence items
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00007795Explore in graph →
Clinical trials
377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (52)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03588091 | Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | completed | Phase 3 | 355 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT02003209 | Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer | completed | Phase 3 | 315 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2025 |
| clinicaltrials |
| NCT03013504 | A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients(TROIKA) | completed | Phase 3 | 503 | Prestige Biopharma LimitedINDUSTRY | 13 | Nov 6, 2024 | clinicaltrials |
| NCT04957212 | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer | completed | Phase 3 | 214 | CinnagenINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06107790 | Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer | completed | Phase 3 | 570 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT04109391 | Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 | completed | Phase 3 | 338 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Oct 26, 2022 | clinicaltrials |
| NCT03556358 | Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer | completed | Phase 3 | 809 | Tanvex BioPharma USA, Inc.INDUSTRY | 10 | Jan 14, 2022 | clinicaltrials |
| NCT00005970 | Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer | completed | Phase 3 | 3,436 | National Cancer Institute (NCI)NIH | 4 | Aug 14, 2020 | clinicaltrials |
| NCT00390455 | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | completed | Phase 3 | 295 | National Cancer Institute (NCI)NIH | 1 | Dec 20, 2019 | clinicaltrials |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | completed | Phase 3 | 961 | GBG Forschungs GmbHOTHER | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00003440 | Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic | completed | Phase 3 | 580 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Aug 22, 2025source: clinicaltrials